Medesis Pharma is a clinical-stage Pharmaceutical Biotechnology company developing innovative technology (AONYS®) for the delivery of therapeutic molecules to treat diseases with no current efficacious treatment.
Medesis Pharma is listed on Euronext Growth Paris.
Legal structure :
- Montpellier (France) Headquarters
- Montreal (Canada) 100% subsidiary. Medesis Pharma Inc. is a subsidiary for collaborations with McGill University and the University of Montreal.
Medesis Pharma already has a long history.
Research program began in 1991 with the initiation of program investigating a plant extract for treatment of metabolic anomalies linked to insulin resistance.
After ten years of chemical purification (and more than 2,000 candidate molecules tested on animal models) the constituents of our micro-emulsion were identified, which evolved into a strictly pharmaceutical formulation: the water/oil micro-emulsion that we have called Aonys® .
Our technology and its multiple applications are protected by 11 international patents
Medesis Pharma was created in April 2003 and has, over the years, developed a substantial pipeline that now leads several future drugs into the clinic.
Our mission and our values
The primary mission of the company is medical — that is, the development of new drugs to treat diseases that are, to date, lacking effective treatments (e.g. neurodegenerative diseases, cancers and viral diseases, in particular COVID-19). We also have a financial objective, because only appropriate funding makes it possible to implement development plans and the validation of the efficacy and safety of each drug.
Since its creation, Medesis Pharma has been financed by private individuals who believed in our projects and their prospects (230 historical shareholders). In February 2021, the Company’s listing on Euronext Growth Paris created real momentum for our clinical development with patients.
To summarize the values of the company:
Always dreaming that we can achieve it.
Having the courage to move forward in a world of multiple constraints.
Combining rigor with enthusiasm!
Jean-Claude Maurel created Medesis Pharma in 2003. He trained as a medical doctor and has more than 30 years of experience in the research, development and marketing of drugs.
He created the Natura Medica laboratory in 1985, a pharmaceutical laboratory that developed and marketed extracts of medicinal plants, which was then sold in 1990 to IPSEN-BEAUFOUR.
In 1991, he created a research company that, after 10 years of chemical and pharmacological explorations, discovered the lipid constituents that today are the foundation of AONYS® technology.
In 2003, he created Medesis Pharma by bringing together patents and technical know-how.
Member of the Executive Board, Director of Medical Affairs and Clinical Development
Solene Guilliot is a doctor of pharmacy with over 7 years of experience in medical affairs and clinical development. Previously, she held several international positions at Sanofi Genzyme and Bristol-Myers Squibb (United States, Canada, Germany and France). With her experience in neuroscience and immunology, in industry and in hospitals, she joined Medesis Pharma in 2021.
Member of the Executive Board, Administrative and Financial Director
With more than 20 years of experience, including 10 years as an executive assistant in an international drilling company, Tessa Olivato, of Franco-Belgian nationality, joined Medesis Pharma in 2014. In June 2021, she took up the post of Administrative and Financial Director.
Chairman of the Board
Olivier Connes is Chairman of the Management Board of the Meridis Group, a supplier of industrial equipment specializing in planning, food processing and research. Partner at Solid Surfaces Applications, a company specializing in the wood and PVC joinery sector.